COMPANY PROFILE

Nuwacell

Explore full profile

Full-chain iPSC platform: cell bank, reagents and allogeneic cell therapies

Hefei, ChinaFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Nuwacell

Nuwacell (中盛溯源) is a Hefei-based iPSC technology company founded in 2016, building an end-to-end platform from clinical-grade iPSC reprogramming and culture reagents through directed differentiation to cell-drug development. Products include a large Chinese-population iPSC super-donor bank, iMSC and iNK cell therapies that have received CDE clinical clearances (among the first China iMSC/iNK IND approvals), and reagents for stem-cell research. The company is a national specialized-and-innovative 'little giant' and closed a RMB 150 million Series B first close in 2024 led by Guangzhou Industrial Investment with Junlian Capital and others. Display name standardized to Nuwacell / 中盛溯源.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Hefei, China
Employees: 7
Open positions: None listed
Dealroom signal: 46.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Apr 2025	$2.8M	$138M	Canton Venture Capital · Hefei Industry Investment Group	↗
SERIES BOther financing	Nov 2024	$21M	$138M	Guoju Venture Capital · Guangzhou Industrial Investment Group · Legend Capital	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Nuwacell website traffic

Latest recorded traffic for Nuwacell is 490 monthly website visits, up 226.7% over the last three months. Nuwacell's team grew 0% over the past year.

Latest monthly visits490 3-month web change+226.7% 1-year team growth0%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational	44	$217M	$700M
CNCereCura NanotherapeuticsPioneering RNA nanomedicine to treat intractable brain diseases using lipid nanoparticle technology	Vancouver, Canada	Operational
POPorosomePorosome Therapeutics, Inc. - Porosome Discovery Promises to Revolutionize Modern Medicine	Boston, United States	Operational
NTNeusignal TherapeuticsTherapeutic drugs for Central Nervous System diseases	Tokyo, Japan	Operational
ATAer TherapeuticsClinical-stage biopharmaceutical company developing inhaled treatments for muco-obstructive lung diseases	San Francisco, United States	Operational
STSensorium TherapeuticsDedicated to enhancing mental well-being and improving the human experience at scale	Boston, United States	Operational
DBDemeter Bio-TechProvideS solutions based on microalgae technology for the sustainable development of society	China	Operational
BDBiomirror DiagnosticsA medical device and diagnostics company focusing on women's health	Seattle, United States	Operational